Abstract 3361: Phosphoglucose Isomerase/autocrine Motility Factor Mediates Epithelial-Mesenchymal Transition Regulated by Mir-200 in Breast Cancer Cells

Aamir Ahmad,Amro Aboukameel,Dejuan Kong,Zhiwei Wang,Avraham Raz,Fazlul H. Sarkar
DOI: https://doi.org/10.1158/1538-7445.am2011-3361
IF: 11.2
2011-01-01
Cancer Research
Abstract:Phosphoglucose isomerase/autocrine motility factor (PGI/AMF), a housekeeping gene product that plays a key role in both glycolysis and gluconeogenesis pathways, is associated with invasion and metastasis of cancer cells. PGI/AMF is involved in the induction of Epithelial-to-Mesenchymal transition (EMT) phenotype in breast cancer cells, which leads to increased aggressiveness; however, the molecular mechanism by which PGI/AMF regulates EMT is not known. Here, we show, for the first time, that the over-expression of PGI/AMF leads to an increase in the DNA-binding activity of NF-κB, which in turn causes increased expression of ZEB1/ZEB2. Since microRNA-200s (miR-200s; miR-200a, miR-200b and miR-200c) are known to negatively regulate the expression of ZEB1/ZEB2, we assessed their expression and found that the expression of miR-200s was lost in PGI/AMF over-expressing MCF-10A cells as well as in highly invasive MDA-MB-231 cells, which was consistent with increased expression of ZEB1/ZEB2. Moreover, silencing of PGI/AMF expression in MDA-MB-231 cells led to re-expression of miR-200s, which was associated with the reversal of EMT phenotype i.e. Mesenchymal-to-Epithelial Transition (MET), and these findings were consistent with alterations in the relative expression of epithelial (E-cadherin) and mesenchymal (vimentin, ZEB1, ZEB2) markers, and decreased aggressiveness, as judged by clonogenic, motility and invasion assays. Silencing of PGI/AMF was also found to result in significantly reduced pulmonary metastases in vivo. Collectively, these results suggest, for the first time, the role of miR-200s in PGI/AMF induced EMT-MET, and thus clinical approaches for up-regulation of miR-200s could become a novel therapeutic strategy for the treatment of highly invasive breast cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3361. doi:10.1158/1538-7445.AM2011-3361
What problem does this paper attempt to address?